Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Tetraphase Pharmaceu (TTPH)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Latest Headlines for [[ item.sessionDateDisplayLong ]]
Detailed Research: Economic Perspectives on Tetraphase Pharmaceuticals, Tech Data, Southern National Bancorp of Virginia, Esterline Technologies, Myers Industries, and Hersha Hospitality Trust -- What Drives Growth in Today's Competitive Landscape

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Tetraphase Pharmaceuticals,...

TECD : 85.52 (-0.83%)
MYE : 18.30 (-1.35%)
SONA : 17.41 (+0.17%)
HT : 22.33 (+0.27%)
TTPH : 3.04 (-1.62%)
ESL : 83.00 (+10.01%)
Tetraphase Pharmaceuticals Announces Data from a Pooled Analysis of IGNITE1 and IGNITE4 Phase 3 Trials Evaluating Eravacycline in Complicated Intra-Abdominal Infections at the ASM Microbe 2018 Annual Meeting

Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company focused on developing and commercializing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, recently...

TTPH : 3.04 (-1.62%)
Tetraphase Pharmaceuticals Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company focused on developing and commercializing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today...

TTPH : 3.04 (-1.62%)
Today's Free Research Reports Coverage on Seattle Genetics and Three More Biotech Stocks

Stock Research Monitor: SLS, TTPH, and RARE

SGEN : 70.26 (-0.37%)
TTPH : 3.04 (-1.62%)
Tetraphase Pharmaceuticals Announces Everest Medicines' Submission of an Investigational New Drug Application for Eravacycline in Complicated Intra-Abdominal Infection to the China Food and Drug Administration

Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company focused on developing and commercializing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today...

TTPH : 3.04 (-1.62%)
Tetraphase Pharmaceuticals to Present at the UBS Global Healthcare Conference

Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant infections, announced today that its corporate presentation...

TTPH : 3.04 (-1.62%)
Tetraphase Pharmaceuticals Reports First Quarter 2018 Financial Results and Recent Highlights

Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company focused on developing and commercializing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today...

TTPH : 3.04 (-1.62%)
Recent Analysis Shows Morningstar, Tactile Systems Technology, Allete, Tetraphase Pharmaceuticals, Magellan Health, and Ambarella Market Influences -- Renewed Outlook, Key Drivers of Growth

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Morningstar, Inc. (NASDAQ:MORN),...

TCMD : 55.60 (+2.26%)
AMBA : 38.79 (-2.44%)
MGLN : 91.90 (-3.72%)
MORN : 139.16 (+0.41%)
ALE : 77.52 (-1.14%)
TTPH : 3.04 (-1.62%)
Blog Exposure - Tetraphase Pharma Announced Data Presentations from IGNITE4 Study at 28th European Congress of Clinical Microbiology and Infectious Diseases

Stock Monitor: Akari Therapeutics Post Earnings Reporting

AKTX : 2.08 (+0.97%)
TTPH : 3.04 (-1.62%)
Tetraphase Pharmaceuticals to Present Data at 28th European Congress of Clinical Microbiology and Infectious Diseases

- Phase 3 IGNITE4 Results in Complicated Intra-Abdominal Infection Recognized as a 'Best Rated Abstract' -

TTPH : 3.04 (-1.62%)
Tetraphase Pharmaceuticals to Present at H.C. Wainwright Annual Global Life Sciences Conference

Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced that...

TTPH : 3.04 (-1.62%)
Tetraphase Pharm Falls 4.18% on Heavy Volume: Watch For Potential Rebound

Tetraphase Pharm (NASDAQ:TTPH) traded in a range yesterday that spanned from a low of $2.89 to a high of $3.20. Yesterday, the shares fell 4.2%, which took the trading range below the 3-day low of $3.00...

TTPH : 3.04 (-1.62%)
New Research: Key Drivers of Growth for First Defiance Financial, Tetraphase Pharmaceuticals, LRAD, LPL Financial, Hubbell, and Castlight Health, inc. -- Factors of Influence, Major Initiatives and Sustained Production

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of First Defiance Financial Corp....

CSLT : 5.40 (+11.34%)
LRAD : 2.95 (-0.67%)
LPLA : 68.81 (+0.31%)
FDEF : 32.72 (+0.25%)
TTPH : 3.04 (-1.62%)
HUBB : 115.25 (-0.29%)
This Morning's Technical Outlook on Generic Drugs Stocks -- Ironwood Pharma, Pacira Pharma, pSivida, and Tetraphase Pharma

WallStEquities.com strives to bring the best free research to the investment community. Today we are offering reports on IRWD, PCRX, PSDV, and TTPH which can be accessed for free by signing up to www.wallstequities.com/registration....

PSDV : 1.22 (+14.02%)
IRWD : 20.02 (-0.20%)
PCRX : 37.25 (+0.68%)
TTPH : 3.04 (-1.62%)
Tetraphase Pharmaceuticals to Present at 17th Annual Needham Healthcare Conference

Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced that...

TTPH : 3.04 (-1.62%)
Tetraphase Pharmaceuticals Reports Fourth Quarter and Full-Year 2017 Financial Results, Highlights Achievements and Key 2018 Milestones

Achieved positive results of Eravacycline in Phase 3 IGNITE 4 clinical trial for cIAI

TTPH : 3.04 (-1.62%)
Look for Shares of Tetraphase Pharm to Potentially Pullback after Yesterday's 1.22% Rise

Tetraphase Pharm (NYSE:TTPH) traded in a range yesterday that spanned from a low of $2.77 to a high of $3.10. Yesterday, the shares gained 1.2%, which took the trading range above the 3-day high of $2.91...

TTPH : 3.04 (-1.62%)
Tetraphase Pharmaceuticals Announces FDA Acceptance for Filing of its NDA Submission for Eravacycline for the Treatment of Complicated Intra-Abdominal Infections (cIAI)

Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company focused on developing and commercializing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today...

TTPH : 3.04 (-1.62%)
Tetraphase Pharmaceuticals Enters into Exclusive Development and Commercialization Agreement with Everest Medicines for Eravacycline in China

Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company focused on developing and commercializing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today...

TTPH : 3.04 (-1.62%)
Options Traders Expect Huge Moves in Tetraphase Pharmaceuticals (TTPH) Stock

Investors in Tetraphase Pharmaceuticals (TTPH) need to pay close attention to the stock based on moves in the options market lately.

TTPH : 3.04 (-1.62%)

Van Meerten Stock Picks

5 Terrific Mid Caps
In this roller coaster market I wanted to find Mid Cap stocks that had consistent price appreciation over the last 6 month period.
EHC -0.38 , FTNT +0.53 , CAKE -0.45 , PLT -0.28 , AEO -0.65
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.
Free Commodities Newsletter

Get prepared for your trading day with

Barchart's Commodity Futures Morning Update Email

InsideFutures Commentary

InsideFutures weekly newsletter features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Friday morning to your inbox.

Agricharts Market Commentary

Today's Commentary

Corn futures closed the week with most contracts 3 to 4 cents higher on Friday. Nearby September was up 4.1% since last Friday, with higher closes every day this week. Solid exports and drier weather fueled some bottom picking and short covering acti...
Read More

Alan Brugler writes this daily agricultural markets overview with opening, midday and closing comments directed at the gain and meat Ag markets.

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.

Free Barchart Webinar